ReviewFrontiers in oncology2026
Gastric metastasis from colorectal cancer: an updated comprehensive review of epidemiology, mechanisms, diagnosis, and management.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is one of the most common and deadly malignancies worldwide, with metastasis being its most lethal feature. Although the liver and lungs are well-recognized sites of metastasis, gastric involvement as a target organ is extremely rare. The exact incidence remains unclear due to the lack of large-scale epidemiological data, and existing literature consists mainly of case reports and empirical risk estimates. This rarity, combined with the frequent misdiagnosis of gastric metastases as primary gastric cancer in clinical practice, makes gastric metastasis from CRC a unique clinical entity characterized by diagnostic challenges and therapeutic difficulties. Analysis of available case reports indicates that the median age at onset is approximately 65 years, with the left-sided colon being the most common primary site. The interval between diagnosis of the primary tumor and development of gastric metastasis ranges from 6 months to 10 years. Diagnosis primarily relies on a combination of immunohistochemical markers-CK7-/CK20+/CDX2+-while the emerging marker SATB2 further enhances diagnostic specificity. Currently, there is limited high-level evidence-based guidance for treatment; systemic chemotherapy regimens used for metastatic CRC-such as FOLFOX or FOLFIRI combined with targeted therapy-are typically employed. Surgical resection may be considered for isolated, resectable gastric metastases, but overall prognosis remains poor, with a median survival of approximately 12 months. This review comprehensively summarizes the epidemiological characteristics, molecular mechanisms, clinicopathological diagnosis, routes and mechanisms of metastasis, clinical manifestations, diagnostic strategies, differential diagnosis, treatment options, and prognostic factors associated with gastric metastasis from CRC, aiming to provide clinicians with a comprehensive understanding of this rare condition and to serve as a reference for future research and clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.